Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

152.35 +2.62 (+1.75%)
Streaming Delayed Price Updated: 12:38 PM EDT, Apr 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
56 57 Next >
News headline image
J&J Shatters Estimates as Oncology and MedTech Power 2026 Outlook Higher
Johnson & Johnson (NYSE: JNJ) delivered a robust first-quarter 2026 earnings report on April 14, 2026, handily beating Wall Street expectations and signaling a successful navigation of the long-feared... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
MedTech Surge and Oncology Resilience Drive Johnson & Johnson to Q1 Earnings Beat
In a resounding display of corporate resilience, Johnson & Johnson (NYSE:JNJ) reported first-quarter 2026 financial results that surpassed Wall Street expectations, signaling a successful navigation of... 
Via MarketMinute
Topics Bankruptcy Earnings Economy
Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Case for Dividend Investors ↗
Via Chartmill
Novartis AG-Sponsored ADR (NYSE:NVS): A Methodical Pick for Steady Dividend Income ↗
Via Chartmill
News headline image
Big Pharma Deepens AI Ties. What It Means For Novo, Novartis. ↗
Novo Nordisk and Novartis deepened their ties to AI companies on Tuesday. And they won't be the last pharma giants to do so. 
Via Investor's Business Daily
Topics Artificial Intelligence
News headline image
The Radiopharmaceutical Renaissance: A Deep Dive into Telix Pharmaceuticals (TLX)
As of April 13, 2026, Telix Pharmaceuticals Limited (ASX: TLX; NASDAQ: TLX) stands as a pivotal player in the rapidly evolving field of radiopharmaceuticals—a sector that has transformed from a niche... 
Via Finterra
Topics Economy Initial Public Offering
News headline image
3 Low-Volatility ETFs for Peace of Mind in Turbulent Times ↗
Amid confusion about the future trajectory of the war in Iran, the possibility of a continued ceasefire, and the potential implications for the price of oil—and the market in general—it's... 
Via MarketBeat
Topics ETFs
News headline image
The "Liberation Day" Shockwave: US Finalizes 100% Tariffs on Branded Pharmaceutical Imports
In a move that has sent shockwaves through the global healthcare industry, the U.S. Administration officially finalized a sweeping new trade policy on April 6, 2026, imposing 100% tariffs on branded... 
Via MarketMinute
Topics Economy World Trade
News headline image
Trump Issues Landmark Executive Order: 100% Tariffs on Imported Patented Drugs to Force Onshoring
WASHINGTON, D.C. — In a move that has sent shockwaves through the global healthcare industry, President Trump signed a sweeping executive order yesterday, April 2, 2026, imposing a baseline 100% tariff... 
Via MarketMinute
Topics Economy Government Lawsuit
News headline image
Legend Biotech (LEGN) Q4 2024 Earnings Transcript ↗
Legend Biotech (LEGN) Q4 2024 Earnings Transcript 
Via The Motley Fool
Topics Earnings Economy World Trade
News headline image
Legend Biotech (LEGN) Q1 2025 Earnings Transcript ↗
Legend Biotech (LEGN) Q1 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Biogen's $5.6 Billion Acquisition of Apellis: A Strategic Pivot into Rare Kidney Diseases
In a move that signals a decisive shift away from its traditional focus on neuroscience, Biogen (NASDAQ: BIIB) announced today, March 31, 2026, that it has entered into a definitive agreement to... 
Via MarketMinute
News headline image
Could Investing $10,000 in VYMI Make You a Millionaire? ↗
If you want to be a millionaire faster than the S&P 500 index can deliver, this international dividend stock ETF could be the ticket. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
Novartis Bets $2 Billion To Deepen Allergy Drug Pipeline ↗
Novartis expands allergy portfolio with $2B acquisition of Excellergy Inc. and their next-gen anti-IgE therapy Exl-111. 
Via Benzinga
News headline image
International ETFs: EEM and IEFA Offer Distinct Global ETF Choices ↗
Expense, risk, and sector focus set these two ETFs apart—see which aligns better with your global investing strategy. 
Via The Motley Fool
Topics ETFs
News headline image
Sarepta Therapeutics (SRPT) Stock Surges 34.98% on Breakthrough Clinical Data
CAMBRIDGE, MA — March 26, 2026 — Shares of Sarepta Therapeutics (NASDAQ:SRPT) skyrocketed 34.98% in heavy trading today, marking the biotech giant's most explosive single-day gain in over two years.... 
Via MarketMinute
News headline image
The Second Act: A Deep-Dive into Corcept Therapeutics and the FDA Approval of Lifyorli
March 26, 2026 Introduction Yesterday, March 25, 2026, Corcept Therapeutics (NASDAQ: CORT) reached a defining milestone that has fundamentally altered its investment profile: the early FDA approval of... 
Via Finterra
Topics Economy Intellectual Property
News headline image
The $6.7 Billion Pivot: A Deep Dive into Terns Pharmaceuticals (TERN) and the Merck Acquisition
On this Wednesday, March 25, 2026, the biotechnology sector has been electrified by the announcement that Merck & Co. (NYSE: MRK) will acquire Terns Pharmaceuticals, Inc. (NASDAQ: TERN) in an all-cash... 
Via Finterra
Topics Initial Public Offering Intellectual Property World Trade
News headline image
Retirees: Collect a High Dividend While Diversifying Your Portfolio With This ETF ↗
The Vanguard International High Dividend Yield ETF holds more than 1,500 stocks and yields 3.3%. 
Via The Motley Fool
Topics ETFs Retirement
News headline image
3 ETFs Built for the Volatile Market We're Seeing in March 2026 ↗
These ETFs can handle volatile markets. 
Via The Motley Fool
Topics ETFs Economy Stocks
News headline image
Novartis Strikes $3 Billion Deal For Next-Gen Breast Cancer Drug ↗
Novartis to acquire SNV4818 for $3 billion, targeting PIK3CA-mutated breast cancer with a potentially safer, precision-based approach. 
Via Benzinga
News headline image
The High-Stakes Gambit: How Healthcare Giants are 'Front-Loading' Megadeals to Outrun Regulatory Storms
In the face of the most aggressive antitrust environment in decades and the sweeping legislative changes of the 2025 "One Big Beautiful Bill Act" (OBBBA), the healthcare sector has not retreated from... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
Novartis Advances Dermatology Portfolio With Cosentyx FDA Approval For Pediatric Patients ↗
FDA approves Novartis' Cosentyx for moderate to severe hidradenitis suppurativa in patients aged 12 and older, expanding treatment options. 
Via Benzinga
News headline image
VYMI: This International ETF Could Help You Earn Higher Dividends ↗
If you want international stock exposure with a chance for higher dividend yields, this Vanguard ETF could be a good buy. 
Via The Motley Fool
Topics ETFs
News headline image
3 ETFs to Avoid as Oil Shock Hits Markets ↗
Via MarketBeat
Topics ETFs
News headline image
Vertex Pharmaceuticals Surges as Breakthrough Kidney Data Sets New Gold Standard for IgA Nephropathy
Shares of Vertex Pharmaceuticals (Nasdaq: VRTX) climbed more than 8% today, reaching a record high as the biotechnology giant unveiled spectacular interim results from its pivotal Phase 3 RAINIER... 
Via MarketMinute
News headline image
Pfizer (PFE) 2026 Research Feature: The High-Stakes Pivot to Oncology and Obesity
As of today, March 10, 2026, Pfizer Inc. (NYSE: PFE) stands at a pivotal crossroads in its 177-year history. After experiencing a meteoric rise during the COVID-19 pandemic followed by a sobering... 
Via Finterra
Topics Economy Intellectual Property Lawsuit
News headline image
Forget Amarin: This Oft-Overlooked Pharma Powerhouse Is a Better Buy Now ↗
One is speculative, the other is a reliable blue chip company. 
Via The Motley Fool
Topics Intellectual Property
News headline image
As Investors Flee U.S. Equities, This Global ETF Is Outperforming ↗
Via MarketBeat
Topics ETFs
News headline image
Second HeLa Lawsuit Resolved As Novartis Reaches Confidential Settlement ↗
Novartis reached a confidential settlement with Henrietta Lacks' family, resolving a second lawsuit over the nonconsensual use of HeLa cells. 
Via Benzinga
Topics Lawsuit
< Previous 1 2 3 4 5 6 7 8 9
...
56 57 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.